Skip to main content
Premium Trial:

Request an Annual Quote

LetsGetChecked At-Home Molecular SARS-CoV-2 Test Nabs FDA Emergency Use Authorization

NEW YORK – Home health testing company LetsGetChecked announced Friday its Coronavirus Sure-track Test for at-home use received Emergency Use Authorization from the US Food and Drug Administration.

The test is intended for nasal swab specimens self-collected by people at home who have been determined by a healthcare provider to be at risk of being infected with SARS-CoV-2 and prescribed the kit. PrivaPath Labs, a CLIA-certified lab which does business as LetsGetChecked, will perform the RT-PCR testing with results provided within 24 hours. 

According to an FDA document, PrivaPath will use Hologic's Panther Fusion SARS-CoV-2 assay, which received EUA in March, as well as an RNaseP gene RT-PCR test run for each sample to test for the presence of the RNaseP gene to determine appropriate sample collection.

After swab collection, the sample is placed in a solution that deactivates the virus, which LetsGetChecked said ensures shipping providers and lab technicians are protected from infection. The test is available on the company's website for $129 per kit for patients who meet the criteria on a COVID-19 guided risk questionnaire.

The Sure-track Test is the only EUA at-home test that owns all aspects of the testing service, including the collection kit manufacturing process, logistics, lab analysis, and physician approval, the company said in a statement. Patients who test positive can access telehealth services and guidance on next steps from LetsGetChecked's online platform, it added.

LetsGetChecked's lab in Monrovia, California, is currently at a capacity of 300,000 units per week and building towards providing "millions per week" in the future, the company said. Earlier this month, the company closed a $71 million Series C financing round, which it said would help increase manufacturing, supply, and testing capacity for SARS-CoV-2.

The Dublin-based firm rolled out a two-part test for SARS-CoV-2 in March that includes an initial point-of-care lateral flow assay and confirmatory real-time PCR test in its laboratories.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.